Advances in the treatment of intermediate and posterior uveitis

Authors: Fraser-Bell, Samantha; Pavesio, Carlos

Source: Expert Review of Ophthalmology, Volume 3, Number 4, August 2008 , pp. 449-456(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior uveitis. Systemic corticosteroids are often used initially as they are fast acting, potent and inexpensive. However, other agents may be introduced, either owing to a lack of response to the steroids or to reduce the amount of corticosteroid required. This review explores new therapeutic options and will therefore concentrate on newer steroid-sparing immunosuppressives - the antimetabolite mycophenolate mofetil and biological agents, such as infliximab and interferon) - and on local therapy, such as intravitreal injections and implants). Well-conducted, randomized clinical trials are still required to confirm their benefit.

Keywords: adalimumab; anti-VEGF; bevacizumab; etanercept; fluocinolone; infliximab; interferon; mycophenolate mofetil; triamcinolone; uveitis

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.3.4.449

Affiliations: 1: Medical Retinal and Uveitis Department, Moorfields Eye Hospital, London, UK; and, Department of Ophthalmology, Faculty of Medicine, University of Sydney, NSW, Australia., Email: sfraserbell@gmail.com

Publication date: 2008-08-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites